Quantifying preference in drug benefit-risk decisions

Tervonen, Tommi, Angelis, Aris ORCID: 0000-0002-0261-4634, Hockley, Kimberley, Pignatti, Francesco and Phillips, Lawrence D. (2019) Quantifying preference in drug benefit-risk decisions. Clinical Pharmacology and Therapeutics, 106 (5). pp. 955-959. ISSN 0009-9236

Text (Quantifying_preferences_in_drug_benefit_risk_decisions_) - Accepted Version Download (279kB)

• Author
• Author

Abstract

Benefit-risk assessment is used in various phases along the drug lifecycle, such as marketing authorization and surveillance, health technology assessment (HTA), and clinical decisions, to understand whether, and for which patients, a drug has a favorable or more valuable profile with reference to one or more comparators. Such assessments are inherently preference-based as several clinical and nonclinical outcomes of varying importance might act as evaluation criteria, and decision makers must establish acceptable trade-offs between these outcomes. Different healthcare stakeholder perspectives, such as those from patients and healthcare professionals, are key for informing benefit-risk trade-offs. However, the degree to which such preferences inform the decision is often unclear as formal preference-based evaluation frameworks are generally not used for regulatory decisions, and, if used, rarely communicated in HTA decisions. We argue that for better decisions, as well as for reasons of transparency, preferences in benefit-risk decisions should more often be quantified and communicated explicitly.

Item Type:	Article
Additional Information:	© 2019 The Authors Clinical Pharmacology & Therapeutics © American Society for Clinical Pharmacology and Therapeutics
Divisions:	Health Policy LSE Health
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	29 Mar 2019 00:13
Last Modified:	17 Mar 2024 19:45
URI:	http://eprints.lse.ac.uk/id/eprint/100324

Actions (login required)

View Item